Immunicon Corp, Huntingdon Valley, Pa, reports it is considering financial and strategic alternatives for the company—including the sale of some or all of its businesses.

The company has retained Stifel, Nicolaus & Co as its financial advisor during the process.

Company officials plan to keep mum until the board of directors approves the next move. 

Immunicon is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, with an initial focus on cancer disease management. It has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes.